{
    "meta": {
        "portal_name": "pharmacokinetics",
        "language": "en",
        "updated": "20150427"
    },
    "schema": {
        "html:portal": "http://en.recuweb.com/pharmacokinetics/",
        "graph:videos": "http://en.recuweb.com/graph/v1.0/pharmacokinetics/pharmacokinetics/videos.json",
        "graph:news": "http://en.recuweb.com/graph/v1.0/pharmacokinetics/pharmacokinetics/news.json",
        "graph:blogs": "http://en.recuweb.com/graph/v1.0/pharmacokinetics/pharmacokinetics/blogs.json"
    },
    "items": {
        "virtual-strategy.com/2015/04/basilea-reports-isavuconazole-and-ceftobiprole-data-to-be-presented-at-eccmid": {
            "title": "Basilea reports isavuconazole and ceftobiprole data to be presented at ECCMID - Virtual-Strategy...",
            "snippet": "Basilea reports isavuconazole and ceftobiprole data to be presented at ECCMIDVirtual-Strategy Magazine (press release)In addition, pharmacokinetics, safety and tolerability of high-dose ceftobiprole in the intensive care setting are being presented.",
            "date": "2015-04-24",
            "categories": "pharmacokinetics",
            "tags": "dose,dose-ceftobiprole,ceftobiprole,intensive,intensive-care,intensive-care-setting,care,care-setting,setting,setting-are-being,presented,safety,safety-and-tolerability,tolerability,tolerability-of-high,high,press,press-release,release,reports,isavuconazole,data,basilea,eccmid,addition,pharmacokinetics",
            "recuweb_url": "http://en.recuweb.com/pharmacokinetics/virtual-strategy.com/2015/04/basilea-reports-isavuconazole-and-ceftobiprole-data-to-be-presented-at-eccmid",
            "resource_url": "http://news.google.com/?hl=en&q=pharmacokinetics%2Bpharmacokinetics&output=atom&nord=1",
            "source_url": "http://virtual-strategy.com/2015/04/24/basilea-reports-isavuconazole-and-ceftobiprole-data-be-presented-eccmid"
        },
        "aidsmap.com/2015/04/merck-hcv-combination-achieves-90%-cure-in-advanced-cirrhosis-aidsmap": {
            "title": "Merck HCV combination achieves 90% cure in advanced cirrhosis - aidsmap...",
            "snippet": "aidsmapMerck HCV combination achieves 90% cure in advanced cirrhosisaidsmapThe study was divided into two phases: a phase 2 study in which the pharmacokinetics of grazoprevir and elbasvir were assessed in cirrhotic patients in comparison to a...",
            "date": "2015-04-24",
            "categories": "pharmacokinetics",
            "tags": "assessed,patients,study,phase,pharmacokinetics",
            "recuweb_url": "http://en.recuweb.com/pharmacokinetics/aidsmap.com/2015/04/merck-hcv-combination-achieves-90%-cure-in-advanced-cirrhosis-aidsmap",
            "resource_url": "http://news.google.com/?hl=en&q=pharmacokinetics%2Bpharmacokinetics&output=atom&nord=1",
            "source_url": "http://aidsmap.com/Merck-HCV-combination-achieves-90-cure-in-advanced-cirrhosis/page/2964259/"
        },
        "thestreet.com/2015/04/basilea-reports-isavuconazole-and-ceftobiprole-data-to-be-presented-at-eccmid": {
            "title": "Basilea Reports Isavuconazole And Ceftobiprole Data To Be Presented At ECCMID...",
            "snippet": "In addition, pharmacokinetics, safety and tolerability of high-dose ceftobiprole in the intensive care setting are being presented. HAP is one of the most common infectious diseases acquired in hospitals, affecting% of hospitalized patients.",
            "date": "2015-04-23",
            "categories": "infectious-diseases,pharmacokinetics",
            "tags": "patients,dose,dose-ceftobiprole,ceftobiprole,intensive,intensive-care,intensive-care-setting,care,care-setting,setting,setting-are-being,presented,safety,safety-and-tolerability,tolerability,tolerability-of-high,high,basilea,reports,isavuconazole,data,eccmid,addition,pharmacokinetics",
            "recuweb_url": "http://en.recuweb.com/pharmacokinetics/thestreet.com/2015/04/basilea-reports-isavuconazole-and-ceftobiprole-data-to-be-presented-at-eccmid",
            "resource_url": "http://www.bing.com/news/search?first=1&q=pharmacokinetics&format=RSS&cc=us",
            "source_url": "http://thestreet.com/story/13125060/1/basilea-reports-isavuconazole-and-ceftobiprole-data-to-be-presented-at-eccmid.html"
        },
        "seekingalpha.com/2015/04/corbus-gets-5-million-from-cystic-fibrosis-foundation-crbp-seeking-alpha": {
            "title": "Corbus Gets 5 Million From Cystic Fibrosis Foundation (CRBP) - Seeking Alpha...",
            "snippet": "Corbus Gets 5 Million From Cystic Fibrosis Foundation (CRBP)Seeking AlphaPhase 1 Study 1: This study evaluated the safety, tolerability, and pharmacokinetics of a single oral dose of Resunab in healthy adult males over a dose range of 1-10 mg in...",
            "date": "2015-04-23",
            "categories": "pharmacokinetics",
            "tags": "healthy,adult,dose,oral,study,evaluated,safety,tolerability,pharmacokinetics",
            "recuweb_url": "http://en.recuweb.com/pharmacokinetics/seekingalpha.com/2015/04/corbus-gets-5-million-from-cystic-fibrosis-foundation-crbp-seeking-alpha",
            "resource_url": "http://news.google.com/?hl=en&q=pharmacokinetics&output=atom&nord=1",
            "source_url": "http://seekingalpha.com/article/3092876-corbus-gets-5-million-from-cystic-fibrosis-foundation"
        },
        "businesswire.com/2015/04/pomalyst-pomalidomide-label-update-including-progression-free-and-business-wire-press": {
            "title": "POMALYST (pomalidomide) Label Update Including Progression-Free and... - Business Wire (press...",
            "snippet": "POMALYST (pomalidomide) Label Update Including Progression-Free and...Business Wire (press release)The influence of renal and hepatic impairment on the safety, efficacy, and pharmacokinetics of pomalidomide has not been evaluated. Avoid POMALYST in...",
            "date": "2015-04-23",
            "categories": "business,pharmacokinetics",
            "tags": "evaluated,safety,press,press-release,release,free,pharmacokinetics",
            "recuweb_url": "http://en.recuweb.com/pharmacokinetics/businesswire.com/2015/04/pomalyst-pomalidomide-label-update-including-progression-free-and-business-wire-press",
            "resource_url": "http://news.google.com/?hl=en&q=pharmacokinetics%2Bpharmacokinetics&output=atom&nord=1",
            "source_url": "http://businesswire.com/news/home/20150423006761/en/POMALYST\u00ae-pomalidomide-Label-Update-Including-Progression-Free-Survival"
        },
        "4-traders.com/2015/04/suda-artimist-peer-review-publications": {
            "title": "Suda: ArTimist peer review publications...",
            "snippet": "Professor Davis is also the chairman of the Company's Clinical Advisory Board for ArTiMist. The first article, which is titled, 'Pharmacokinetics of a novel sublingual spray formulation of the antimalarial drug artemether in healthy adults', sets...",
            "date": "2015-04-23",
            "categories": "pharmacokinetics",
            "tags": "healthy,adults,clinical,pharmacokinetics,drug",
            "recuweb_url": "http://en.recuweb.com/pharmacokinetics/4-traders.com/2015/04/suda-artimist-peer-review-publications",
            "resource_url": "http://www.bing.com/news/search?first=1&q=pharmacokinetics&format=RSS&cc=us",
            "source_url": "http://4-traders.com/SUDA-LTD-12120694/news/Suda--ArTimist-peer-review-publications-20249809/"
        },
        "empr.com/2015/04/fda-hypertension-tx-currently-in-shortage": {
            "title": "FDA: Hypertension Tx Currently in Shortage...",
            "snippet": "However, Bystolic 10mg tablets are available to cover the demand for the 20mg tablets. RELATED: Beta-Blocker Pharmacokinetics Chart Bystolic is a cardioselective beta-blocker indicated for the treatment of hypertension in adults 18 years of age.",
            "date": "2015-04-22",
            "categories": "pharmacokinetics",
            "tags": "treatment,adults,pharmacokinetics,currently",
            "recuweb_url": "http://en.recuweb.com/pharmacokinetics/empr.com/2015/04/fda-hypertension-tx-currently-in-shortage",
            "resource_url": "http://www.bing.com/news/search?first=1&q=pharmacokinetics&format=RSS&cc=us",
            "source_url": "http://empr.com/fda-hypertension-treatment-currently-in-shortage/article/410440/"
        },
        "uml.edu/2015/04/announcing-new-dean-of-school-pharmacy-and-pharmaceutical-sciences": {
            "title": "Announcing New Dean of School of Pharmacy and Pharmaceutical Sciences...",
            "snippet": "As an educator, he designed and delivered courses such as drug discovery and development, biopharmaceutics and pharmacokinetics, and toxicokinetics. He has written two books as sole author in pharmacokinetics and toxicokinetics. UMass Lowell's...",
            "date": "2015-04-21",
            "categories": "school,pharmacokinetics",
            "tags": "written,biopharmaceutics,discovery,development,designed,school,drug,pharmacokinetics",
            "recuweb_url": "http://en.recuweb.com/pharmacokinetics/uml.edu/2015/04/announcing-new-dean-of-school-pharmacy-and-pharmaceutical-sciences",
            "resource_url": "http://www.bing.com/news/search?first=1&q=pharmacokinetics&format=RSS&cc=us",
            "source_url": "http://uml.edu/Today/Submissions/2015/2015-04-21-07-58-32-Announcing-New-Dean-of-Pharmacy-and.aspx"
        },
        "globenewswire.com/2015/04/clinical-phase-ii-study-with-neurostat-for-traumatic-brain-injury-passes": {
            "title": "Clinical Phase II study with NeuroSTAT for traumatic brain injury passes safety evaluation...",
            "snippet": "The study focuses on safety and pharmacokinetics, and 10 of 20 planned patients have been enrolled so far. A phase III study is currently being planned and designed. NeuroVive has secured orphan drug designation for NeuroSTAT for moderate and...",
            "date": "2015-04-21",
            "categories": "pharmacokinetics",
            "tags": "study,currently,designed,patients,safety,clinical,phase,pharmacokinetics,drug",
            "recuweb_url": "http://en.recuweb.com/pharmacokinetics/globenewswire.com/2015/04/clinical-phase-ii-study-with-neurostat-for-traumatic-brain-injury-passes",
            "resource_url": "http://www.bing.com/news/search?first=1&q=pharmacokinetics&format=RSS&cc=us",
            "source_url": "http://globenewswire.com/news-release/2015/04/21/726350/0/en/Clinical-Phase-II-study-with-NeuroSTAT-for-traumatic-brain-injury-passes-safety-evaluation.html?f=22&fvtc=7"
        },
        "businesswire.com/2015/04/genzyme-initiates-phase-2a-clinical-trial-to-evaluate-oral-therapy": {
            "title": "Genzyme Initiates Phase 2a Clinical Trial to Evaluate Oral Therapy for Fabry Disease...",
            "snippet": "The safety, tolerability and pharmacokinetics of GZ/SAR402671 will also be assessed. Genzyme plans to enroll nine treatment-na\u00efve male adult patients with Fabry disease in this international, multicenter study. Fabry disease is a rare lysosomal...",
            "date": "2015-04-21",
            "categories": "therapy,pharmacokinetics",
            "tags": "study,adult,patients,treatment,assessed,tolerability,oral,clinical,phase,safety,pharmacokinetics",
            "recuweb_url": "http://en.recuweb.com/pharmacokinetics/businesswire.com/2015/04/genzyme-initiates-phase-2a-clinical-trial-to-evaluate-oral-therapy",
            "resource_url": "http://www.bing.com/news/search?first=1&q=pharmacokinetics&format=RSS&cc=us",
            "source_url": "http://businesswire.com/news/home/20150421005272/en/Genzyme-Initiates-Phase-2a-Clinical-Trial-Evaluate"
        }
    }
}